• Nifedipine: Research Context and Evidence

  2026-10-04

  Nifedipine, also identified in the supplied product information as BAY-a-1040, is presented as an L-type calcium-channel blocker with potential applications in calcium signaling, muscle physiology, iron metabolism modulation, and research on Phytophthora capsici. The available evidence varies substantially in provenance: several claims come from a supplier description, whereas the supplied peer-reviewed study by Bi et al. examines PXR activation and CYP metabolism in rats, not nifedipine. This overview separates reported findings from interpretation, explains the relevance of the PXR–CYP study, and defines the limits of applying those results to nifedipine or other biological systems.

• Chronic Cabozantinib Signaling in RCC

  2026-10-03

  A 2026 phosphoproteomic study shows that acute and chronic Cabozantinib exposure produce distinct remodeling of phosphorylation networks in renal cell carcinoma cells. Chronic exposure maintained MET activation-loop suppression while enriching selective adhesion-, stress-, and MAPK/AP-1-associated programs, with modest, context-dependent changes in motility.

• ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors

  2026-10-02

  The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted RTK and PDGFR inhibitors in high-grade glioma cells. Its results also support evaluating RTK inhibitor–temozolomide combinations while incorporating ATRX status into interpretation of translational and clinical studies.

• 25-Hydroxycholesterol Reprograms TAMs

  2026-10-01

  Xiao et al. identify a CH25H–25-hydroxycholesterol circuit that accumulates in tumor-associated macrophage lysosomes and activates AMPKα through GPR155–mTORC1 signaling. The resulting AMPKα–STAT6–ARG1 pathway reinforces immunosuppression, whereas CH25H targeting improves T-cell surveillance and anti-PD-1 responses in tumor models.

• Ferrostatin-1 (Fer-1): Reliable Assays

  2026-10-01

  This scenario-based guide explains how Ferrostatin-1 (Fer-1), SKU A4371, can strengthen ferroptosis experiments through appropriate controls, solvent handling, dose interpretation, and orthogonal validation. It connects product specifications with recent liver cancer findings to help researchers distinguish ferroptosis from overlapping oxidative and apoptotic phenotypes.

• Quercetin: From PI3K Inhibition to Assay Design

  2026-09-30

  Quercetin is more than a PI3K inhibitor: it is a versatile research probe for connecting kinase signaling, mitochondrial apoptosis, cell cycle regulation, and neuroinflammation. This article translates recent LPS-depression findings into practical, cross-domain assay and interpretation strategies.

• Multimotor Control of Lipid Droplet Transport in TNTs

  2026-09-30

  This ACS Nano study combines optical trapping, confocal imaging, and microtubule-polarity mapping to quantify how kinesin and dynein coordinate lipid droplet transport through tunneling nanotubes. Its force distributions show that multimotor engagement and force coupling, rather than isolated motor activity, sustain bidirectional long-range transport in a highly viscoelastic intercellular environment.

• In Vitro Drug Response: Growth Arrest vs Cell Death

  2026-09-29

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anticancer drug response. This framework supports more informative time-course and assay interpretation in preclinical cancer research, while highlighting why a single viability endpoint can obscure drug-response biology.

• Testosterone Bounce in Degarelix-Treated Prostate Cancer

  2026-09-29

  This retrospective study identified testosterone bounce, defined by recovery above 20 ng/dL after reaching a nadir below that threshold, as a marker associated with longer overall and cancer-specific survival in patients receiving degarelix. The findings support serial testosterone assessment as a complementary prognostic approach, while the absence of an association with progression-free survival highlights important limits to interpretation.

• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-09-28

  This case report describes radiographic reduction of metastatic intra-abdominal desmoplastic small round cell tumor after treatment with anlotinib, offering an early clinical signal in a malignancy without standardized therapy. Its value lies in connecting a multi-target tyrosine kinase inhibitor with a rare, aggressive tumor while also illustrating the diagnostic, imaging, and tolerability considerations required for interpretation.

• Anlotinib Hydrochloride: Anti-Angiogenic Evidence

  2026-09-28

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor used in preclinical research on angiogenesis and tumor growth. Evidence links VEGFR2 inhibition with reduced endothelial responses, while reported multi-target activity supports studying PDGFRβ, FGFR1, and ERK signaling in parallel.

• Hoechst 33342 in Fibroblast Senescence Workflows

  2026-09-27

  Use Hoechst 33342 to visualize and count nuclei in live or fixed dermal fibroblasts—an important imaging readout, but not a stand-alone measure of senescence or mitochondrial health. This workflow pairs nuclear labeling with the complementary assays used to study pterostilbene and mitochondrial quality in human dermal fibroblasts.

• Separating Growth Arrest from Cell Death in Cancer Assays

  2026-09-26

  Hannah R. Schwartz’s dissertation highlights a central problem in in vitro cancer-drug evaluation: relative viability and fractional viability are often treated as interchangeable, even though they reflect different components of response. Its findings support measuring growth inhibition and cell killing separately and considering how their relative contributions change over time.

• Bufalin and the CENPA–Glycolysis Axis in HCC

  2026-09-25

  New pre-proof evidence connects Bufalin with CENPA-associated glycolysis, PI3K/AKT signaling, and migration in hepatocellular carcinoma models. This article examines what the findings establish, what remains to be tested, and how translational teams can design stronger validation workflows.

• Anlotinib and Selective VEGFR2 Inhibition in Angiogenesis

  2026-09-25

  The 2018 preclinical study characterized anlotinib as a potent, selective VEGFR2 inhibitor and linked receptor inhibition to reduced endothelial responses and tumor angiogenesis. Its layered biochemical, cell-based, explant, and mouse experiments provide a useful framework for evaluating anti-angiogenic activity, while leaving clinical efficacy and transferability to human tumors unresolved.

8050 records 1/537 page Next 12345 下5页 Last page